Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) - Analysts at HC Wainwright upped their Q3 2025 earnings estimates for Janux Therapeutics in a report issued on Monday, August 11th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of ($0.58) for the quarter, up from their prior estimate of ($0.63). The consensus estimate for Janux Therapeutics' current full-year earnings is ($1.38) per share. HC Wainwright also issued estimates for Janux Therapeutics' Q4 2025 earnings at ($0.72) EPS, FY2025 earnings at ($2.21) EPS, Q1 2026 earnings at ($0.75) EPS, Q2 2026 earnings at ($0.77) EPS, Q3 2026 earnings at ($0.77) EPS, Q4 2026 earnings at ($0.71) EPS, FY2026 earnings at ($2.98) EPS, FY2027 earnings at ($2.82) EPS and FY2028 earnings at ($0.94) EPS.
Separately, Raymond James Financial began coverage on shares of Janux Therapeutics in a research note on Friday, July 11th. They issued an "outperform" rating and a $65.00 target price for the company. One analyst has rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $91.89.
Check Out Our Latest Stock Analysis on Janux Therapeutics
Janux Therapeutics Stock Up 7.1%
JANX opened at $24.27 on Wednesday. The company has a market capitalization of $1.46 billion, a price-to-earnings ratio of -13.48 and a beta of 2.86. The firm has a 50-day moving average price of $24.63 and a 200-day moving average price of $28.69. Janux Therapeutics has a twelve month low of $21.97 and a twelve month high of $71.71.
Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.07).
Hedge Funds Weigh In On Janux Therapeutics
Several hedge funds have recently bought and sold shares of the company. Russell Investments Group Ltd. grew its stake in Janux Therapeutics by 77.7% during the fourth quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock valued at $54,000 after acquiring an additional 442 shares in the last quarter. Avanza Fonder AB grew its stake in Janux Therapeutics by 17.0% during the first quarter. Avanza Fonder AB now owns 3,049 shares of the company's stock valued at $86,000 after acquiring an additional 444 shares in the last quarter. New York State Common Retirement Fund grew its stake in Janux Therapeutics by 3.0% during the first quarter. New York State Common Retirement Fund now owns 16,435 shares of the company's stock valued at $444,000 after acquiring an additional 471 shares in the last quarter. Exchange Traded Concepts LLC grew its stake in Janux Therapeutics by 20.4% during the first quarter. Exchange Traded Concepts LLC now owns 4,043 shares of the company's stock valued at $109,000 after acquiring an additional 686 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its stake in Janux Therapeutics by 6.5% during the first quarter. China Universal Asset Management Co. Ltd. now owns 11,855 shares of the company's stock valued at $320,000 after acquiring an additional 727 shares in the last quarter. Hedge funds and other institutional investors own 75.39% of the company's stock.
About Janux Therapeutics
(
Get Free Report)
Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Janux Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Janux Therapeutics wasn't on the list.
While Janux Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.